Top-News
Pharmazeutika USA

BioMarin Pharmaceutical News

Aktie
WKN:  924801 ISIN:  US09061G1013 US-Symbol:  BMRN
75,80 €
+0,58 €
+0,77%
09.05.24 09:30:14
Handeln Depot/Watchlist
Aktienanzahl *
187,70 Mio.
Marktkapitalisierung *
14,12 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
Nasdaq Composite Index
IR-Website
zur Website
*Stand: 10.08.2023
Weiter aufwärts? Long handeln - Jetzt mit Hebel 6,44: ME4CET

BioMarin Pharmaceutical News

08.05.24 - PR Newswire
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV PR Newswire
04.05.24 - PR Newswire
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-​Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting PR Newswire
24.04.24 - PR Newswire
BioMarin Reports Record Financial Results for the First Quarter 2024
BioMarin Reports Record Financial Results for the First Quarter 2024 PR Newswire
10.04.24 - PR Newswire
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET PR Newswire
12.03.24 - PR Newswire
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and ...
07.03.24 - PR Newswire
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer PR Newswire
01.03.24 - PR Newswire
BioMarin Scheduled to Participate in March Investor Conferences
BioMarin Scheduled to Participate in March Investor Conferences PR Newswire
22.02.24 - PR Newswire
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024 PR Newswire
13.02.24 - wallstreet:online Zentralredaktion
Tech-Analyse: Nvidia und elf weitere Wachstumsperlen, deren KGV für sich spricht!
Die Nvidia-​Aktie hat ihren Wert im vergangenen Jahr mehr als verdoppelt. Angesichts dieses Laufes könnte man meinen, die Aktie wäre alles andere als günstig bewertet. Das sei ...
08.02.24 - PR Newswire
BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET
BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET PR Newswire
06.02.24 - PR Newswire
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-​rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders ...
03.01.24 - PR Newswire
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA PR Newswire
20.12.23 - PR Newswire
BioMarin Announces Governance Enhancements and Value Creation Initiatives
BioMarin Announces Governance Enhancements and Value Creation Initiatives PR Newswire
28.11.23 - PR Newswire
BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany
BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-​rvox) for Severe Hemophilia A in ...
01.11.23 - PR Newswire
BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year PR Newswire
01.11.23 - PR Newswire
BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer
BioMarin Announces Retirement of Jean-​Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer PR Newswire
20.10.23 - PR Newswire
U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia
U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia PR Newswire
17.10.23 - PR Newswire
BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET
BioMarin to Host Third-​Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET PR Newswire
21.09.23 - PR Newswire
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology ...
15.09.23 - PR Newswire
BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia
BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia PR Newswire

Newssuche

Videos

newspaper
07.05.24 +6,80%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »